MCID: OVR060
MIFTS: 46

Ovary Epithelial Cancer

Categories: Endocrine diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Ovary Epithelial Cancer

MalaCards integrated aliases for Ovary Epithelial Cancer:

Name: Ovary Epithelial Cancer 12 15
Epithelial Tumor of Ovary 12 73
Ovarian Surface Epithelial-Stromal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2152
NCIt 50 C4381
SNOMED-CT 68 237057005
UMLS 73 C0341823

Summaries for Ovary Epithelial Cancer

Disease Ontology : 12 An ovarian cancer that is derives from ovarian surface epithelium.

MalaCards based summary : Ovary Epithelial Cancer, also known as epithelial tumor of ovary, is related to malignant ovarian surface epithelial-stromal neoplasm and mixed epithelial tumor of ovary. An important gene associated with Ovary Epithelial Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Carboplatin and Indinavir have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ovary Epithelial Cancer

Diseases related to Ovary Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 malignant ovarian surface epithelial-stromal neoplasm 26.8 ACSBG1 AKT1 AREG ARID1A BRCA1 BRCA2
2 mixed epithelial tumor of ovary 12.2
3 borderline epithelial tumor of ovary 12.2
4 hereditary site-specific ovarian cancer syndrome 11.2 BRCA1 BRCA2
5 tuberculous salpingitis 11.0 BRCA1 BRCA2 ERBB2
6 synchronous bilateral breast carcinoma 11.0 BRCA1 BRCA2 TP53
7 cerebellar angioblastoma 11.0 TP53 WT1
8 endometrioid ovary carcinoma 11.0
9 breast reconstruction 11.0 BRCA1 BRCA2
10 uterine body mixed cancer 11.0 ARID1A ERBB2 TP53
11 nosophobia 11.0 BRCA1 BRCA2
12 papillary serous adenocarcinoma 11.0 BRCA1 KRT7 TP53
13 cancerophobia 11.0 BRCA1 BRCA2
14 mutagen sensitivity 10.9 BRCA1 BRCA2 TP53
15 gastric papillary adenocarcinoma 10.9 ERBB2 TP53
16 breast squamous cell carcinoma 10.9 ERBB2 PIK3CA TP53
17 bilateral breast cancer 10.9 BRCA1 BRCA2 ERBB2
18 lobular neoplasia 10.9 BRCA1 CDH1 ERBB2
19 vulvar intraepithelial neoplasia 10.9 CDH1 MMP2 TP53
20 cystadenofibroma 10.9 BRCA1 BRCA2 KRT7
21 esophagus adenocarcinoma 10.9 ERBB2 PIK3CA TP53
22 mucoepidermoid esophageal carcinoma 10.9 CEACAM5 TP53
23 granulosa cell tumor of the ovary 10.9 ERBB2 KRT7 TP53
24 hidradenocarcinoma 10.9 ERBB2 KRT7 TP53
25 acinar cell carcinoma 10.9 BRCA2 KRT7 TP53
26 female reproductive endometrioid cancer 10.9 KRT7 TP53 WT1
27 ovarian clear cell adenocarcinoma 10.9 ARID1A HNF1B PIK3CA
28 nephrogenic adenoma of urinary bladder 10.9 KRT7 PAX8
29 nasal cavity adenocarcinoma 10.9 KRAS KRT7 TP53
30 sweat gland cancer 10.9 ERBB2 KRT7 TP53
31 gallbladder squamous cell carcinoma 10.9 CEACAM5 ERBB2 TP53
32 signet ring cell adenocarcinoma 10.9 CDH1 KRT7 TP53
33 uterine corpus serous adenocarcinoma 10.9 BRCA1 BRCA2 ERBB2 TP53
34 breast cystic hypersecretory carcinoma 10.9 CDH1 ERBB2
35 fallopian tube adenocarcinoma 10.8 BRCA1 BRCA2 ERBB2 TP53
36 dysgerminoma of ovary 10.8 BRCA1 BRCA2 WT1
37 hereditary breast ovarian cancer syndrome 10.8 BRCA1 BRCA2 TP53
38 adult hepatocellular carcinoma 10.8 PIK3CA TP53
39 female breast cancer 10.8 BRCA1 BRCA2 ERBB2 TP53
40 barrett's adenocarcinoma 10.8 ERBB2 KRAS TP53
41 bladder squamous cell carcinoma 10.8 ERBB2 PIK3CA TP53
42 biliary tract neoplasm 10.8 KRAS KRT7 TP53
43 microcystic meningioma 10.8 CDH1 MMP2 VEGFA
44 pancreatic ductal carcinoma 10.8 KRT7 TP53 VEGFA
45 sporadic breast cancer 10.8 BRCA1 BRCA2 ERBB2 TP53
46 cerebral convexity meningioma 10.8 CDH1 TP53
47 pseudomyxoma peritonei 10.8 KRAS KRT7 TP53
48 endocervical adenocarcinoma 10.8 KRT7 PAX8 TP53
49 glycogen-rich clear cell breast carcinoma 10.8 BRCA1 BRCA2 KRT7 TP53
50 anal squamous cell carcinoma 10.8 AKT1 PIK3CA TP53

Graphical network of the top 20 diseases related to Ovary Epithelial Cancer:



Diseases related to Ovary Epithelial Cancer

Symptoms & Phenotypes for Ovary Epithelial Cancer

GenomeRNAi Phenotypes related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.94 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.94 ARID1A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.94 BRCA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.94 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.94 BRCA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.94 BRCA1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.94 WT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.94 HNF1B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.94 PAX8
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.94 ARID1A BRCA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.94 ARID1A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 HNF1B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.94 HNF1B BRCA1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.94 ARID1A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.94 ARID1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.94 WT1 HNF1B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.94 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.94 PAX8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.94 PAX8
20 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.94 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.94 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.94 PAX8
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.94 WT1 HNF1B ARID1A PAX8 BRCA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.94 WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.94 HNF1B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.94 HNF1B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.94 BRCA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.94 BRCA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.94 ARID1A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.94 HNF1B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.94 HNF1B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.94 PAX8
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.94 WT1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.94 PAX8
35 Decreased viability in esophageal squamous lineage GR00235-A 9.73 BRCA2 CDH1 ERBB2 HNF1B ARID1A KRAS

MGI Mouse Phenotypes related to Ovary Epithelial Cancer:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 BRCA2 ERBB2 CDH1 MMP2 KRAS PAX8
2 growth/size/body region MP:0005378 10.46 BRCA2 ERBB2 CDH1 MMP2 KRAS PAX8
3 endocrine/exocrine gland MP:0005379 10.44 BRCA2 ERBB2 CDH1 KRAS PAX8 HNF1B
4 cardiovascular system MP:0005385 10.42 ERBB2 CDH1 MMP2 KRAS PAX8 TP53
5 embryo MP:0005380 10.42 BRCA2 ERBB2 CDH1 KRAS PAX8 HNF1B
6 cellular MP:0005384 10.41 CDH1 BRCA2 ERBB2 BRCA1 KRAS KRT7
7 mortality/aging MP:0010768 10.4 BRCA2 ERBB2 CDH1 HNF1B MMP2 KRAS
8 immune system MP:0005387 10.35 CDH1 BRCA2 BRCA1 HNF1B MMP2 KRAS
9 neoplasm MP:0002006 10.23 BRCA2 ERBB2 CDH1 MMP2 KRAS PIK3CA
10 integument MP:0010771 10.22 CDH1 BRCA2 ERBB2 BRCA1 KRAS TP53
11 muscle MP:0005369 10.22 ERBB2 HNF1B MMP2 KRAS TP53 PIK3CA
12 digestive/alimentary MP:0005381 10.19 BRCA1 CDH1 BRCA2 ERBB2 KRAS TP53
13 nervous system MP:0003631 10.17 BRCA1 BRCA2 ERBB2 MMP2 KRAS PAX8
14 normal MP:0002873 10.15 BRCA2 ERBB2 CDH1 MMP2 KRAS PAX8
15 craniofacial MP:0005382 10.14 ERBB2 MMP2 KRAS PAX8 TP53 ARID1A
16 limbs/digits/tail MP:0005371 10.11 BRCA1 BRCA2 ERBB2 KRAS TP53 RSF1
17 reproductive system MP:0005389 10.1 BRCA2 ERBB2 CDH1 KRAS PAX8 PIK3CA
18 no phenotypic analysis MP:0003012 10.06 CDH1 KRAS ESS2 TP53 PIK3CA PAX8
19 renal/urinary system MP:0005367 9.92 BRCA1 KRT7 HNF1B KRAS TP53 PAX8
20 respiratory system MP:0005388 9.76 BRCA1 ERBB2 MMP2 KRAS TP53 AKT1
21 skeleton MP:0005390 9.73 BRCA2 ERBB2 BRCA1 MMP2 KRAS PAX8
22 vision/eye MP:0005391 9.28 MMP2 KRAS TP53 PIK3CA RSF1 PAX8

Drugs & Therapeutics for Ovary Epithelial Cancer

Drugs for Ovary Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
2
Indinavir Approved Phase 2 150378-17-9 5362440
3
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
4
Belinostat Approved, Investigational Phase 2 866323-14-0
5
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
6
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
7 Fondaparinux Approved, Investigational Phase 2 104993-28-4
8
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
9
Amifostine Approved, Investigational Phase 2,Phase 1 20537-88-6 2141
10
Etoposide Approved Phase 2 33419-42-0 36462
11
Ifosfamide Approved Phase 2 3778-73-2 3690
12
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
13
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
14
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
15
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
16
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
17
Squalamine Investigational Phase 2 148717-90-2
18
Veliparib Investigational Phase 2 912444-00-9 11960529
19 Angiogenesis Inhibitors Phase 2,Phase 1
20 Angiogenesis Modulating Agents Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 2
22 Anti-Infective Agents Phase 2,Phase 1
23 Protective Agents Phase 2,Phase 1
24 Anti-HIV Agents Phase 2
25 Anti-Retroviral Agents Phase 2
26 Antiviral Agents Phase 2,Phase 1
27 Cytochrome P-450 CYP3A Inhibitors Phase 2
28 Cytochrome P-450 Enzyme Inhibitors Phase 2
29 HIV Protease Inhibitors Phase 2,Phase 1
30 Liver Extracts Phase 2,Phase 1
31
protease inhibitors Phase 2,Phase 1
32 Imatinib Mesylate Phase 2 220127-57-1 123596
33 Protein Kinase Inhibitors Phase 2,Phase 1
34 Histone Deacetylase Inhibitors Phase 2,Phase 1
35 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
36 Antibodies Phase 2,Phase 1
37 Antibodies, Monoclonal Phase 2,Phase 1
38 Endothelial Growth Factors Phase 2,Phase 1
39 Immunoglobulin G Phase 2,Phase 1
40 Immunoglobulins Phase 2,Phase 1
41 Mitogens Phase 2,Phase 1
42 Anticoagulants Phase 2
43 Antithrombin III Phase 2
44 Antithrombins Phase 2
45 Factor Xa Inhibitors Phase 2
46 Fibrinolytic Agents Phase 2
47 PENTA Phase 2
48 Serine Proteinase Inhibitors Phase 2
49 Androgens Phase 1, Phase 2
50 Adjuvants, Immunologic Phase 2,Phase 1

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer Unknown status NCT00021385 Phase 2 carboplatin;squalamine lactate
2 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
3 Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor Completed NCT00039585 Phase 2 imatinib mesylate
4 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed NCT00301756 Phase 2 Belinostat
5 Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01540565 Phase 2 Veliparib
6 Gefitinib in Treating Patients With Cervical Cancer Completed NCT00049556 Phase 2 gefitinib
7 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
8 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
9 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
10 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
11 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
12 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 Selumetinib Sulfate
13 Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients Not yet recruiting NCT03509246 Phase 2 Pegylated liposomal doxorubicin plus Bortezomib
14 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
15 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
16 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
17 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
18 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
19 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
20 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
21 LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer Completed NCT00005858 Phase 1
22 BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer Completed NCT00005807 Phase 1 ixabepilone
23 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
24 Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Recruiting NCT02520115 Phase 1 Dexamethasone;Valproic Acid
25 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
26 Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer Completed NCT01096394
27 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
28 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
29 Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer Completed NCT00383279 Not Applicable
30 Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer Completed NCT00003763 Not Applicable
31 Inherited Susceptible Genes Among Epithelial Ovarian Cancer Recruiting NCT03015376

Search NIH Clinical Center for Ovary Epithelial Cancer

Genetic Tests for Ovary Epithelial Cancer

Anatomical Context for Ovary Epithelial Cancer

MalaCards organs/tissues related to Ovary Epithelial Cancer:

41
Ovary, Breast, Brain, Liver, Endothelial, Lung, Colon

Publications for Ovary Epithelial Cancer

Variations for Ovary Epithelial Cancer

Expression for Ovary Epithelial Cancer

Search GEO for disease gene expression data for Ovary Epithelial Cancer.

Pathways for Ovary Epithelial Cancer

Pathways related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 AKT1 AREG BRCA1 BRCA2 ERBB2 KRAS
2
Show member pathways
13.55 AKT1 AREG BRCA1 ERBB2 HNF1B KRAS
3
Show member pathways
13.53 AKT1 ERBB2 HNF1B KRAS KRT7 MMP2
4
Show member pathways
13.39 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
5
Show member pathways
12.99 AKT1 AREG BRCA1 ERBB2 KRAS PIK3CA
6 12.79 AKT1 AREG ERBB2 KRAS TP53 VEGFA
7
Show member pathways
12.76 AKT1 CDH1 KRAS PIK3CA VEGFA
8
Show member pathways
12.76 AKT1 ERBB2 KRAS PIK3CA TP53
9
Show member pathways
12.73 AKT1 CDH1 ERBB2 KRAS PIK3CA TP53
10
Show member pathways
12.72 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
11
Show member pathways
12.7 AKT1 KRAS MMP2 PIK3CA VEGFA
12
Show member pathways
12.61 AKT1 KRAS PIK3CA TP53 VEGFA
13
Show member pathways
12.61 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
14
Show member pathways
12.6 AKT1 AREG BRCA2 CDH1 ERBB2 KRAS
15
Show member pathways
12.54 AKT1 ERBB2 KRAS PIK3CA TP53
16 12.54 BRCA1 ERBB2 KRAS PIK3CA TP53 VEGFA
17
Show member pathways
12.52 AKT1 AREG CDH1 ERBB2 KRAS MMP2
18
Show member pathways
12.47 AKT1 ERBB2 KRAS PIK3CA TP53
19
Show member pathways
12.47 AKT1 AREG ERBB2 KRAS PIK3CA TP53
20 12.44 AKT1 KRAS PIK3CA TP53
21
Show member pathways
12.42 AKT1 BRCA1 KRAS PIK3CA VEGFA
22 12.38 AKT1 BRCA2 CDH1 ERBB2 KRAS MMP2
23
Show member pathways
12.35 AKT1 ERBB2 KRAS PIK3CA
24 12.3 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
25
Show member pathways
12.27 AKT1 AREG KRAS VEGFA
26
Show member pathways
12.25 AKT1 KRAS TP53 VEGFA
27
Show member pathways
12.22 AKT1 KRAS PIK3CA TP53
28 12.21 AKT1 KRAS PIK3CA TP53
29 12.2 AKT1 CDH1 KRAS MMP2 TP53 VEGFA
30
Show member pathways
12.18 AKT1 ERBB2 KRAS PIK3CA
31
Show member pathways
12.18 AKT1 KRAS PIK3CA TP53
32 12.17 AKT1 ERBB2 KRAS PIK3CA TP53
33
Show member pathways
12.15 AKT1 ERBB2 MMP2 PIK3CA
34 12.12 AKT1 MMP2 PIK3CA TP53 VEGFA
35 12.1 AKT1 KRAS PIK3CA TP53
36 12.1 AKT1 BRCA1 BRCA2 CDH1 KRAS TP53
37
Show member pathways
12.09 AKT1 AREG BRCA1 CDH1 KRAS PIK3CA
38
Show member pathways
12.07 AKT1 ERBB2 PIK3CA TP53
39 12.05 AKT1 KRAS PIK3CA TP53
40 12.03 AKT1 KRAS PIK3CA TP53
41 12.03 AKT1 ERBB2 KRAS PIK3CA TP53
42 12.02 AKT1 MMP2 TP53 VEGFA
43
Show member pathways
11.99 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
44 11.94 AKT1 KRAS MMP2 PIK3CA VEGFA
45 11.93 AKT1 ERBB2 PIK3CA VEGFA
46
Show member pathways
11.83 BRCA1 BRCA2 TP53
47
Show member pathways
11.83 AKT1 KRAS PIK3CA
48 11.79 AKT1 BRCA1 ERBB2 PIK3CA TP53
49 11.74 AKT1 PAX8 PIK3CA
50
Show member pathways
11.72 AKT1 PIK3CA TP53

GO Terms for Ovary Epithelial Cancer

Cellular components related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 AKT1 AREG ARID1A BRCA1 BRCA2 ERBB2

Biological processes related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 AREG BRCA2 ERBB2 TP53
2 negative regulation of apoptotic process GO:0043066 9.87 AKT1 CEACAM5 ERBB2 HNF1B TP53 VEGFA
3 positive regulation of protein phosphorylation GO:0001934 9.85 AKT1 ERBB2 KRAS VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 AREG TP53 VEGFA
5 liver development GO:0001889 9.8 HNF1B KRAS PIK3CA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 PIK3CA VEGFA
7 response to glucocorticoid GO:0051384 9.78 ACSBG1 AREG KRAS
8 positive regulation of MAP kinase activity GO:0043406 9.77 ERBB2 KRAS VEGFA
9 kidney development GO:0001822 9.71 HNF1B PAX8 VEGFA WT1
10 ERBB2 signaling pathway GO:0038128 9.65 ERBB2 KRAS PIK3CA
11 cytokine-mediated signaling pathway GO:0019221 9.63 AKT1 KRAS MMP2 PIK3CA TP53 VEGFA
12 anoikis GO:0043276 9.61 AKT1 PIK3CA
13 phosphatidylinositol 3-kinase signaling GO:0014065 9.61 AKT1 ERBB2 PIK3CA
14 cellular response to gonadotropin stimulus GO:0071371 9.6 PAX8 WT1
15 mesonephric tubule development GO:0072164 9.58 HNF1B PAX8
16 pronephros development GO:0048793 9.56 HNF1B PAX8
17 epidermal growth factor receptor signaling pathway GO:0007173 9.56 AKT1 AREG KRAS PIK3CA
18 metanephric S-shaped body morphogenesis GO:0072284 9.54 PAX8 WT1
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.54 BRCA1 BRCA2 TP53
20 metanephric epithelium development GO:0072207 9.52 PAX8 WT1
21 cellular response to indole-3-methanol GO:0071681 9.51 BRCA1 CDH1
22 positive regulation of gene expression GO:0010628 9.5 AKT1 BRCA1 ERBB2 HNF1B KRAS TP53
23 chordate embryonic development GO:0043009 9.49 BRCA1 BRCA2
24 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.46 HNF1B PAX8
25 positive regulation of transcription, DNA-templated GO:0045893 9.32 AKT1 ARID1A BRCA1 BRCA2 CDH1 HNF1B
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 AKT1 BRCA1 HNF1B PAX8 TP53 VEGFA

Molecular functions related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AKT1 AREG ARID1A BRCA1 BRCA2 CDH1
2 identical protein binding GO:0042802 9.7 AKT1 BRCA2 CDH1 CEACAM5 ERBB2 TP53
3 transcription regulatory region DNA binding GO:0044212 9.02 BRCA1 HNF1B PAX8 TP53 WT1

Sources for Ovary Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....